All posts by medical

The Growth Factors Market To Show Constructive Disruption With ~ US$ 2.5 Bn – TechnoWeekly

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

According to the latest market report published by PMR on thegrowth factors marketduring2014 2018and forecast for2019 2029,the global growth factors market is projected to reach~ US$ 2.5 Bn by the end of 2029.The growth factors market is expected to grow with a CAGR of~ 8 %during the forecast period2019-2029.

Growth factors are gaining high demand for cell culture-based research in the field of oncology, wound management, cardiovascular, and other medical fields. The growth factors market is expected to grow at a significant rate due to the growing demand for stem cell biology research.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4456

Company Profiles

Increasing Life Science Research Funding Favors the Growth of the Market

Growth factors & cytokines play an important role in life science-based research. Various government, private, and commercial organizations are providing funding for life science-based research for the development of new products to reduce illness and economic burden. Investments in R&D are likely to increase in countries such as China, India, and South Korea.

Moreover, the increasing demand for growth factors in tissue regeneration and regenerative medicines is also expected to propel the growth of the global growth factors market. The global growth factors market is expected to witness significant growth over the forecast period due to increasing oncological and stem cell biology research funding, and the development of new products for wound management.

However, the high cost of some growth factors and lack of skilled professionals are among the major factors hindering the growth of the growth factors market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4456

Interleukins to Gain Significant Market Value Shares in the Global Growth Factors Market

Based on product type, the global growth factors market has been segmented into Interleukin (ILs), Epidermal Growth Factors (EGFs), Transforming Growth Beta Factor (TGF-beta), Fibroblast Growth Factors (FGFs), Insulin-Like Growth Factors (IGFs), Platelet-Derived Growth Factors (PDGFs), Hepatocyte Growth Factors (HGFs), Vascular Endothelial Growth Factors (VEGFs), Tumor Necrosis Factors (TNFs), and others.

In terms of revenue, the Interleukins (ILs) are expected to hold a prominent share in the growth factors market revenues, through the end of forecast period.

Based on application, the global growth factors market has been segmented into oncology, dermatology, cardiovascular disease & diabetes, hematology, wound healing, cell culture, and others. Cell culture will remain the most prominent application area of growth factors, as indicated by PMRs study. By end user, the global growth factors market continues to witness a strong boost through the growing demand from contract research organizations, pharmaceutical & biotechnology companies, and research centers & academic institutes.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4456

North America Holds a Prominent Revenue Share in the Global Growth Factors Market

Geographically, the global growth factors market has been segmented into East Asia, South Asia, Oceania, North America, Latin America, Europe, and the Middle East & Africa. North America holds a prominent revenue share in the global growth factors market as of 2018.

The East Asia growth factors market is expected to grow with a significant growth rate over the forecast period. Countries such as the U.S., China, Germany, Japan, the UK, France, and India accounted for a significant revenue share in the global growth factors market in 2018.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Read this article:
The Growth Factors Market To Show Constructive Disruption With ~ US$ 2.5 Bn - TechnoWeekly

90% efficacy for Pfizers COVID-19 mRNA vaccine is striking. But we need to wait for the full data – Australian Times

Harry Al-Wassiti, Monash University; Colin Pouton, Monash University, and Kylie Quinn, RMIT University

German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.

These early results are what is known as an interim analysis. Its an early look at the data before a study is complete, to understand if there is any indication of whether the vaccine might work.

Currently, this trial has enrolled 43,538 volunteers, giving half the volunteers two doses of the vaccine and the other half two doses of a placebo. These volunteers then continued their normal lives, but they were monitored for any symptoms that could be COVID-19, with testing to confirm.

Analysis of 94 volunteers with confirmed COVID-19 suggests the vaccine has an efficacy of over 90%.

This means that if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one out of ten would now get sick.

There is more data to come. This is a press release and the data have not undergone peer-review through scientific publication, although it has been assessed by an independent monitoring board. The study also wont be complete until 164 volunteers have confirmed COVID-19, and the estimate of efficacy may therefore change. Finally, the volunteers must be monitored for a defined period of time after vaccination for any side effects and this must be completed.

Important questions also remain. Its unclear how long protection will last, as this study has only been underway for three months. Its unclear if this vaccine protects against severe disease or if this vaccine will work equally well in everyone. For example, a phase 1 clinical trial with this vaccine showed that immune responses were lower in older people.

But 90% efficacy is striking. To give some context, the US Food and Drug Administration indicated they would licence a SARS-CoV-2 vaccine with 50% efficacy. The flu vaccine often provides around 60% efficacy and the mumps vaccine, which is currently the fastest vaccine ever made at four years, provides around 88% efficacy.

The BioNTech/Pfizer vaccine could outstrip that, after just nine months of development. This level of efficacy means virus transmission could be very effectively controlled.

That has the research community excited. It bodes well for other vaccines currently being tested for SARS-CoV-2 and we could end up with multiple successful vaccines. This would be great because some might work better in certain populations, like older people.

Multiple vaccines could also be manufactured using a broad range of established infrastructure, which would accelerate vaccine distribution.

The BioNTech/Pfizer vaccine is whats called an mRNA vaccine.

As this article by Associate Professor Archa Fox, an expert on molecular cell biology from the University of Western Australia, explains:

mRNA vaccines are coated molecules of mRNA, similar to DNA, that carry the instructions for making a viral protein.

After injection into muscle, the mRNA is taken up by cells. Ribosomes, the cells protein factories, read the mRNA instructions and make the viral protein. These new proteins are exported from cells and the rest of the immunisation process is identical to other vaccines: our immune system mounts a response by recognising the proteins as foreign and developing antibodies against them.

The problem is Australia cant make mRNA vaccines onshore yet.

The Australian government has an agreement for ten million doses of the BioNTech/Pfizer vaccine. Since this vaccine requires two doses, this agreement is sufficient for five million Australians. Its unclear how long it will take until any vaccine is widely available, but we may hear more about this in the coming weeks and months.

The vaccine requires storage at a temperature below -60. This will certainly be a challenge for shipping to Australia and local distribution, although not impossible. One solution to this problem is to form vaccination centres to roll out the vaccine once it becomes available. In a briefing by Pfizer, the company said it will use ultra-low temperature shipment strategies and the vaccine can then be distributed on dry-ice.

Currently, Australia has no capacity to produce mRNA on a commercial scale given the technologys novelty. But we (the authors) and others have been working to coordinate and build the manufacturing capacity in Australia for future mRNA vaccine and therapeutics. With financial support aimed at private-public mRNA manufacturing collaboration, Australia can equip itself with this vital technological asset.

Harry Al-Wassiti, Bioengineer and Research Fellow, Monash University; Colin Pouton, Professor of Pharmaceutical Biology, Monash University, and Kylie Quinn, Vice-Chancellors Research Fellow, School of Health and Biomedical Sciences, RMIT University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
90% efficacy for Pfizers COVID-19 mRNA vaccine is striking. But we need to wait for the full data - Australian Times

Mimicking the early development of the heart – Tech Explorist

Once upon a time, growing organs in the lab were science fiction. But now, methods such as stem cell biology and tissue engineering have turned that fiction into reality with the advent of organoids.

Organoids are tiny lab-grown tissues and organs that are anatomically correct and physiologically functional.

Recently, the lab of Matthias Ltolf at the School of Life Sciences at EPFL has successfully produced a mouse heart organoid in its early embryonic stages. Scientists grew organoids from mouse embryonic stem cells, which, under the right conditions, can self-organize into structures that mimic aspects of the architecture, cellular composition, and function of tissues found in real organs.

Placed in cell-culture under specific conditions, the embryonic stem cells from a three-dimensional aggregate called a gastruloid, which can follow the mouse embryos developmental phases.

This studys idea was that the mouse gastruloid could be utilized to mimic the beginning phases of heart development in the embryo. This is a new use of organoids, which are commonly developed to mimic adult tissues and organs.

Also, there are three features of mouse gastruloids that make them a suitable template for mimicking embryonic development: they establish a body plan like real embryos. They show similar gene expression patterns. And when it comes to the heart, which is the first organ to form and function in the embryo, the mouse gastruloid also preserves important tissue-tissue interactions necessary to grow one.

Equipped with this, the scientists exposed mouse embryonic stem cells to a cocktail of three factors known to promote heart growth. Following 168 hours, the subsequent gastruloids gave early heart development indications: they expressed several genes that regulate cardiovascular development in the embryo. They even generated what resembled a vascular network.

Importantly, scientists found that the gastruloids developed what they call an anterior cardiac crescent-like domain. This structure produced a beating heart tissue, similar to the embryonic heart. As the muscle cells of the embryonic heart, the beating compartment was also sensitive to calcium ions.

Giuliana Rossi, a post-doctoral researcher from Ltolfs laboratory, said,Opening up an entirely new dimension to organoids, the breakthrough work shows they can also be used to mimic embryonic stages of development. One of the advantages of embryonic organoids is that, through the co-development of multiple tissues, they preserve crucial interactions that are necessary for embryonic organogenesis.

The emerging cardiac cells are thus exposed to a context similar to the one that they encounter in the embryo.

The study was conducted in collaboration with Viventis Microscopy, EPFL Bioimaging and Optics Platform, Institut de Biologie du Dveloppement de Marseille, Johns Hopkins University School of Medicine, EPFL Institute of Chemical Sciences and Engineering.

See the rest here:
Mimicking the early development of the heart - Tech Explorist

Global Live Cell Imaging Consumables Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 – The Courier

Global Live Cell Imaging Consumables Market 2020 by Manufacturers, Type and Application, Forecast to 2025 contains an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with market size, estimated from 2020 to 2025. The report encompasses several factors such as global manufacturers, market size, and market factors that affect global contributions. The report discusses factors related to current industry conditions, levels of growth of the industry, demands, business-oriented approaches used by the manufacturers of the Live Cell Imaging Consumables industry in brief about distinct tactics and futuristic prospects. The research throws light on an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production.

The study report analyzes the past market condition and forecasts potential prospects based on comprehensive analysis. The report provides the extensive market share, growth, trends, and forecasts for the 20202025 period. It then studies recent trends, development status, market dynamics (drivers, restraints, and opportunities), supply chain, and competitive landscape. The research report concentrates on leading global players in the global Live Cell Imaging Consumables market report, which includes details such as company profiles, product picture, and specification, creation of R&D, production capability cost, revenue, and contact information. The report is divided into major categories comprising product, distribution channel, application, and end-users.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/66971

Report Synopsis:

Inputs from industry experts have been collected to deliver detailed market analysis. The report encapsulates factors such as market outline, type-based analysis of global Live Cell Imaging Consumables market, application analysis, and end-use. The market analysis report offers market share, demand, and supply ratio, supply chain analysis, and import/export details.

List of top key-players/leading manufacturers of the market: Carl Zeiss AG (Germany), Olympus Corporation (Japan), Molecular Devices, LCC (US), Leica Microsystems (Germany), Becton, Dickinson and Company (US), Nikon Corporation (Japan), Thermo Fisher Scientific, Inc.(US), GE Healthcare (U.K.), PerkinElmer, Inc. (US), Sigma Aldrich Corporation (US)

The most important types of products covered in this report are: Assay Kits, Reagents, Media, Others

The most widely used downstream fields covered in this report are: Cell Biology, Stem Cells, Developmental Biology, Drug Discovery

Regional Overview:

Experts have offered details on the current and the forecast demand made by the main regions. The report also offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. Moreover, global Live Cell Imaging Consumables market size, share, supply, demand, consumption, price, import, export, type, and application segment information by region has been included in the report.

It also provides market size and forecast estimates from the year 2020 to 2025 with respect to major regions, namely; North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/66971/global-live-cell-imaging-consumables-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Research Objectives:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more from the original source:
Global Live Cell Imaging Consumables Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - The Courier

Cautious optimism in the vaccine hunt – Cosmos

By Harry Al-Wassiti and Colin Pouton, Monash University, and Kylie Quinn, RMIT University

German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.

These early results are what is known as an interim analysis. Its an early look at the data before a study is complete, to understand if there is any indication of whether the vaccine might work.

Currently, this trial has enrolled 43,538 volunteers, giving half the volunteers two doses of the vaccine and the other half two doses of a placebo. These volunteers then continued their normal lives, but they were monitored for any symptoms that could be COVID-19, with testing to confirm.

Analysis of 94 volunteers with confirmed COVID-19 suggests the vaccine has an efficacy of over 90%.

This means that if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one out of ten would now get sick.

There is more data to come. This is a press release and the data have not undergone peer-review through scientific publication, although it has been assessed by an independent monitoring board. The study also wont be complete until 164 volunteers have confirmed COVID-19, and the estimate of efficacy may therefore change. Finally, the volunteers must be monitored for a defined period of time after vaccination for any side effects and this must be completed.

Important questions also remain. Its unclear how long protection will last, as this study has only been underway for three months. Its unclear if this vaccine protects against severe disease or if this vaccine will work equally well in everyone. For example, a phase 1 clinical trial with this vaccine showed that immune responses were lower in older people.

But 90% efficacy is striking. To give some context, the US Food and Drug Administration indicated they would licence a SARS-CoV-2 vaccine with 50% efficacy. The flu vaccine often provides around 60% efficacy and the mumps vaccine, which is currently the fastest vaccine ever made at four years, provides around 88% efficacy.

The BioNTech/Pfizer vaccine could outstrip that, after just nine months of development. This level of efficacy means virus transmission could be very effectively controlled.

That has the research community excited. It bodes well for other vaccines currently being tested for SARS-CoV-2 and we could end up with multiple successful vaccines. This would be great because some might work better in certain populations, like older people.

Multiple vaccines could also be manufactured using a broad range of established infrastructure, which would accelerate vaccine distribution.

The BioNTech/Pfizer vaccine is whats called an mRNA vaccine.

As this article by Associate Professor Archa Fox, an expert on molecular cell biology from the University of Western Australia, explains:

mRNA vaccines are coated molecules of mRNA, similar to DNA, that carry the instructions for making a viral protein.

After injection into muscle, the mRNA is taken up by cells. Ribosomes, the cells protein factories, read the mRNA instructions and make the viral protein. These new proteins are exported from cells and the rest of the immunisation process is identical to other vaccines: our immune system mounts a response by recognising the proteins as foreign and developing antibodies against them.

A problem for Australia is that it cant make mRNA vaccines onshore yet.

The Australian government has an agreement for ten million doses of the BioNTech/Pfizer vaccine. Since this vaccine requires two doses, this agreement is sufficient for five million Australians. Its unclear how long it will take until any vaccine is widely available, but we may hear more about this in the coming weeks and months.

The vaccine requires storage at a temperature below -60. This will certainly be a challenge for shipping to Australia and local distribution, although not impossible. One solution to this problem is to form vaccination centres to roll out the vaccine once it becomes available. In a briefing by Pfizer, the company said it will use ultra-low temperature shipment strategies and the vaccine can then be distributed on dry-ice.

Currently, Australia has no capacity to produce mRNA on a commercial scale given the technologys novelty. But we (the authors) and others have been working to coordinate and build the manufacturing capacity in Australia for future mRNA vaccine and therapeutics. With financial support aimed at private-public mRNA manufacturing collaboration, Australia can equip itself with this vital technological asset.

Harry Al-Wassiti, Bioengineer and Research Fellow, Monash University; Colin Pouton, Professor of Pharmaceutical Biology, Monash University, and Kylie Quinn, Vice-Chancellors Research Fellow, School of Health and Biomedical Sciences, RMIT University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Go here to read the rest:
Cautious optimism in the vaccine hunt - Cosmos

Aspiring physician explores the many levels of human health – MIT News

It was her childhood peanut allergy that first sparked senior Ayesha Ngs fascination with the human body. To see this severe reaction happen to my body and not know what was happening that made me a lot more curious about biology and living systems, Ng says.

She didnt exactly plan it this way. But in her three and a half years at MIT, Ng, a biology and cognitive and brain sciences double major from the Los Angeles, California area, has conducted research and taken classes examining just about every level of human health from cellular to societal.

Most recently, her passion for medicine and health equity led her to the National Foundation for the Centers for Disease Control and Prevention (CDC), where, this summer, she worked to develop guidelines for addressing health disparities on state and local health jurisdictions Covid-19 data dashboards. Now, as an aspiring physician amidst the medical school application process, Ng has a sense of how microbiological, physiological, and social systems interact to affect a persons health.

Starting small

Throughout her entire first year at MIT, Ng studied the biology of health at a cellular level. Specifically, she researched the effects of fasting and aging on regeneration of intestinal stem cells, which are located in the human intestinal crypts and continuously self-divide and reproduce. Understanding these metabolic mechanisms is crucial, as their deregulation can lead to age-associated diseases such as cancer.

That experience allowed me to broaden my technical skills, just getting used to so many different types of molecular biological techniques right away, which I really appreciated, Ng says of her time at the Whitehead Institute for Biomedical Research in Professor David Sabatinis lab.

After some time, I realized that I also wanted tostudy sciences at a broader, more macro level, instead of only the microbiology and molecular biology that we were studying in Course 7, Ng says of her biology major.

In addition to studying the biology of cancer, Ng had developed a curiosity about the human brain and how it functions. I was really interested in that, because my grandpa has dementia, Ng says.

Seeing her grandfathers cognitive decline, she was inspired to become involved in MIT BrainTrust, a student organization that offers a social support network for individuals from around the Boston, Massachusetts area who have brain injuries. We have these meetings, in which I serve as one of only one or two students there to facilitate a safe space where we can have all these individuals with brain injury gather, Ng says of the peer-support aspect of the program. They can really share their mutual challenges and experiences.

Investigating the brain

To pursue her interest in brain research and the societal impact of brain injuries, Ng traveled to the University of Hong Kong the summer after her first year as an MIT International Science and Technology Initiatives (MISTI) China Fung Scholar. Working with Professor Raymond Chang, she began to examine neurodegenerative disease and used tissue-clearing techniques to visualize 3D mouse brain structures at cellular resolution. That was personally meaningful for me, to research about that and learn more about dementia, Ng says.

Returning to MIT her sophomore year, Ng was certain that she wanted to continue studying the brain. She began working on Alzheimers research at the MIT Picower Institute for Learning and Memory in the lab of Professor Li-Huei Tsai, the Picower Professor of Neuroscience at MIT. Much existing research into Alzheimers disease has been at the bulk-tissue level, focusing on the neurons role in neurodegeneration associated with aging.

Ngs work with Tsai considers the complexity of alterations across genes and less-abundant cell types, such as microglia, astrocytes, and other supporting glial cells that become dysregulated in the brains of patients with Alzheimers. Considering the interplay between and within cell types during neurodegeneration is most intriguing to her. While some molecular processes are protective, other damaging ones simultaneously occur and can exist even within the same cell type. This intricacy has made the mechanistic basis behind Alzheimers progression elusive and the research that much more crucial.

Its really interesting to see how heterogeneous and complex the responses are in Alzheimer's brains, Ng says of the research program with Tsai, a founding director of MITs Aging Brain Initiative. I really think about these potential new drug targets to improve treatment for Alzheimer's in the future because I have seen, with my grandpa especially, how treatment is really lacking in the neurodegeneration field. Theres no treatment that's been able to stop or even slow the progression of Alzheimer's disease.

Her research project in the Tsai Lab relies on a technology called single-nucleus RNA sequencing (snRNA-seq), which extracts the genomic information contained in individual cells. This is followed by computational dimension reduction and clustering algorithms to examine how Alzheimers disease differentially affects genes and specific cell types.

With that project, we've been able to use single-nucleus RNA sequencing to really look at the brains of human Alzheimer's patients, Ng says. And with the single-cell technology, we're able to look at brain tissue at a much higher resolution, allowing us to see that theres so much heterogeneity within the brain.

After conducting more than a year of Alzheimers research and then taking a human physiology class in her third year, Ng decided to add a second major in brain and cognitive sciences to gain deeper insight specifically into how the nervous system within the body functions.

That class really allowed me to realize that I really love organ systems and wanted to study by looking at more physiological mechanisms, Ng says. It has been really great to, at the end of my college career, really delve more into a very specific system.

Medicine and society

Having gained perspective on cellular and microbiology, and human organ systems, Ng decided to zoom out further, interning this past summer at the National Foundation for the CDC. She found the opportunity through MITs PKG Center, applied as one of 60 candidates, and was selected for a team of four. There, as a member of the CDC Foundations Health Equity Strike Team, she examined how to increase transparency of publicly available Covid-19 data on health disparities and how the narrative tied to health equity can be modified in public health messages. This involved harnessing data about the demographics of those most affected during Covid-19 including how infection and mortality rates differ starkly based on social factors including housing conditions, socioeconomic status, race, and ethnicity.

Thinking about all these factors, we compiled a set of best practices for how to present data about Covid-19, what data should be collected, and tried to push those out to help jurisdictions as best-practice recommendations, Ng says. That did really increase my interest in health equity and made me realize how important public health is as well.

Amidst the Covid-19 pandemic, Ng is spending the first semester of her senior year at home with her family in the Los Angeles area. I really miss the people and not being able to interact with not only other students and peers, but also faculty as well, she says. I really wanted to enjoy time with friends, and just explore more of MIT, too, which I didn't always get the chance to do over the past few years.

Still, she continues to participate in both BrainTrust and MITs Asian Dance team, remotely, through weekly practices on Zoom.

I think dance is one of the biggest de-stressors for me; I had never done dance before going to college. Getting to meet this team and join this community allowed me not only to connect to my Asian cultural roots, but also just expose myself to this new art form where I could really learn how to express myself on stage, Ng says. And that really has been the source of relief for me to just liberate any worries that I have, and has increased my sense of self-awareness and self-confidence.

Armed with the many experiences she has enjoyed at MIT, both in and out of the classroom, Ng plans to continue studying both medicine and public health. Shes excited to explore different potential specialties and is currently most intrigued by surgery. Whichever specialty she may choose, she is determined to include health equity and cultural sensitivity in her practice.

Seeing surgeons, I personally think that being able to physically heal a patient with my own hands, that would be the most rewarding feeling, Ng says. I will strive to, as a physician, use whatever platform that I have to advocate for patients and really drive health-care systems to overcome disparities.

Read more here:
Aspiring physician explores the many levels of human health - MIT News

Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer – BioSpace

Nov. 9, 2020 13:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.

We welcome Steve to Magenta as a seasoned biotech executive with a strong leadership background, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. I look forward to partnering with Steve as we continue to grow Magenta and further establish our long-term clinical and commercial operations.

As Chief Financial and Operating Officer, Mr. Mahoney will serve as a member of the Companys Executive Team and will oversee all aspects of financial planning and analysis, as well as investor community engagement, including investor relations and other external stakeholder communications, in addition to R&D capital allocation strategy and operations and facilities management.

Mr. Mahoney comes to Magenta with more than 20 years of global biotechnology sector industry experience. Most recently, Mr. Mahoney served as President and Chief Operating Officer of Kiniksa Pharmaceuticals, Ltd., where the company raised capital in three private financing rounds, an initial public offering and a follow-on financing. Prior to his time at Kiniksa, Mr. Mahoney served as Chief Commercial Officer, among other executive titles of increasing responsibilities, at Synageva Biopharma. Previous to that, he was Regional Director, Legal Asia Pacific Region for Genzyme Corporation, following other roles for the organization.

Mr. Mahoney holds a JD/MBA from Boston College and a BA from Colorado College.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005177/en/

Excerpt from:
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer - BioSpace

Does Talaris’ Investigational Cell Therapy Have Potential to Be a ‘Pipeline in a Product’? – BioSpace

Photo courtesy of Talaris.

Talaris Chief Executive Officer Scott Requadt sees FCR001, the companys investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications).

In fact, it was that versatility of the products potential that caused Requadt to join the company as CEO in 2018 after the company, known then as Regenerex, secured $100 million in financing. At the time, Requadt helmed the venture capital group Claris that backed the Series A.

I was really enthusiastic about the company and FCR001, Requadt told BioSpace in an interview.

FCR001, an investigational, allogeneic cell therapy, was previously part of Novartis gene and cell therapy unit, until it was dissolved in 2016. When that unit dissolved, rights to FCR001 reverted to Regenerex. With the return of those rights came multiple opportunities in organ transplant and severe autoimmune disorders. Cell therapies can address complex, multi-pathway diseases and Talaris has big plans for the future of FCR001 to help patients acquire or restore immune tolerance.

Our goal is to basically do for immune tolerance what CAR-T has done for oncology, Requadt said. The same product and the same basic biology will be used. We can treat organ transplant and autoimmune diseases in the same manner.

Through FCR001, Talaris will be able to change the underlying pathology of the disease so the immune system no longer sees it as a threat, Requadt said. The companys lead program is in kidney donor transplant, but FCR001, a one-time stem cell therapy, is also being explored as a treatment for scleroderma, a multi-system autoimmune disease. If FCR001 is effective in these areas, Requadt said those successes will pave the way for use in other indications.

This is a pipeline from a single product, Requadt said of FCR001, which has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (FDA).

In July, Kentucky-based Talaris dosed the first patient in its Phase III FREEDOM-1 study of FCR001 in living donor kidney transplant (LDKT) recipients. The trial is expected to enroll 120 adult patients who will receive kidney donations from living donors. The primary endpoint of the study will be the proportion of FCR001 recipients who are free from necessary drugs to maintain immunosuppression without biopsy proven acute rejection at 24 months post-transplant.

Organ transplant patients are required to continue taking drugs to suppress their immune systems to protect the new organ from immune system responses. However, those immunosuppressant treatments drugs are toxic to the kidney and can ultimately kill the transplanted organ in 10 to 15 years. The drugs can also lead to metabolic disorders and cardiovascular issues, Requadt said.

In 2018, Talaris posted positive Phase II data in LDKT recipients, with 70% of patients who received the treatment able to discontinue the use of immunosuppressant drugs. The Phase II data showed that every tolerized patient has been able to remain free of the use of chronic immunosuppressants for up to 10 years. The median follow-up following transplant was five years, with the longest case being a decade. Additionally, Requadt said the company has also seen better kidney functions in recipients who received FCR100 due to the lack of toxicity issues.

While there are other companies exploring similar approaches, Requadt said to his knowledge, no other group has a 10-year data set that demonstrates the safety and efficacy of a treatment like FRC001.

Not only has Talaris seen the impressive results in removing patients from the anchor of immunosuppressant drugs, Requadt said the use of FCR001 decreased the risk of rejection in patients whose biomarkers did not have as high a match with the kidney donors.

In addition to the Phase III study in LDKT patients, Talaris also has plans to conduct a Phase II study in LDKT Delayed Tolerance Induction and will begin research in Deceased Donor Kidney Transplant patients.

Talaris will also use FCR001 in the treatment of diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma, a rare and potentially fatal chronic autoimmune disease which causes progressive scarring, or fibrosis, of the bodys connective tissues. Autologous hematopoietic stem cell transplant has been shown to halt organ damage and induce remission of the disease. However, with the use of a patients own stem cells, there is a risk of disease recurrence. Also, some patients must undergo full myeloablative conditioning with or without total body irradiation, which is associated with direct organ toxicity and increased risk of future cancers. Talaris aims to harness the power of FCR001 and use stem cells from donors to lower those risks and provide an opportunity for these patients, Requadt said.

For all of these indications were using the same product and were using the same protocols with patients and were treating the patients in the same way. This has the potential to be paradigm shifting, Requadt said.

View original post here:
Does Talaris' Investigational Cell Therapy Have Potential to Be a 'Pipeline in a Product'? - BioSpace

Want to Calm Your Anxiety in Just 8 Minutes? Neuroscience Says Take a Deep Breath and Listen to This – Inc.com

What if I could showyou a way to calm anxiety in just a few minutes, using principles of neuroscience?

It's not a permanent solution. But I remembered reading about thisyears ago, and I tried it this week.

Frankly, I was blown away at how quickly and effectively it worked.

It has to do with listening to a single, eight-minute audio track that was designed and recorded in a way to trigger specific neurological reactions in your brain.

A colleague here on Inc.com wrote once that it reduces anxiety by 65 percent.I admit that I approached it with skepticism, but since it's only eight minutes, and it required almost zero effort, I gave it a try.

The audio track is included at the bottom of this article, if you'd rather skip ahead. ButI think it helps to put all of thisin context first.

More than half of Americans anticipated Election Day this yearwould be the most stressful day of their lives.Add coronavirus, the economic situation, and the general anxiety that many of us feel as a product of early 21st century life?

The word I settle on is "SOBAR," for "stressed out beyond all recognition."

Sometimes, the solution is therapy or medical help. I've certainly availed myself of these at times; it's wildly outdated to think there's any stigma associated with seeking professional help for mental health.

But there are also some very simple things that you can do: Short, intense periods of exercise are highly effective, as isbeing intentional about spending time with friends (even virtually).

Meditation works, as does adding plants and other greenery to your work space. Oh, and going for an "awe walk" in nature, as my colleagues Minda Zetlin and Jessica Stillman have reported on recently, yields fascinating results.

(Based on their advice, I took an "awe walk" of my own on Election Day; it helped a bit, and I got some great photos out of it.)

Butthis eight-minute musical interlude might well be the most intriguing.

It dates back to 2011, when a British band called Marconi Union teamed up with sound therapists to create a track called "Weightlessness" that would stimulate specific neurological reactions when people listened to it.

Among them: a lower heart rate, lower blood pressure, and reduced levels of cortisol, a stress hormone.

Researchers said they then played the song for a group of 40 women, tracking their breathing, brain activity, and blood pressure, and found it to be 11 percent more relaxing than the next-most-stress-reducing song they couldfind, according to results published in the British newspaper,The Telegraph.

"The song...contains a sustaining rhythm that starts at 60 beats per minute and gradually slows to around 50. While listening, your heart rate gradually comes to match that beat," Lyz Cooper, founder of the British Academy of Sound Therapy, told the newspaper.

The fact that the song is almost exactly eight minutesis important, she added, because, "it takes about five minutes for this process, known as entrainment, to occur."

Additional elements, include the structure of thegaps between the song's notes (designed to "create a feeling of euphoria and comfort," according to Cooper), and the fact that there is "no repeating melody, which allows your brain to completely switch off because you are no longer trying to predict what is coming next."

The whole trick comes down to research that shows that "music works at a very deep level within the brain, stimulating not only those regions responsible for processing sound but also ones associated with emotions," said Dr. David Lewis-Hodgson, a neuropsychologist who oversaw the study.

Anyway, given where we are in the world, and despite my skepticism for quick fixes, I tried it.

Reader, it worked. During the time that I listened to the song--fully aware of what it was designed to do--I felt myself relaxing.

The mild sinus headache I'd been enduring disappeared. I could feel my breathing and heart rate slow. A feeling of calmness enveloped me.I began to hear a faint ringing sound--almost like a pleasurable version of tinnitus.

Again, this is not a cure-all. It's certainly not a substitute for combining all the habits I listed above, or for professional help.But if you've got anxietyand you've got eight minutes, you might find it really interesting.

The track is embedded below, andyou can find it pretty much every other place you'd download music, too.

It worked for me. I'd love to hear if it worksfor you, too.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

Read more from the original source:
Want to Calm Your Anxiety in Just 8 Minutes? Neuroscience Says Take a Deep Breath and Listen to This - Inc.com

Neuroscience Market Analysis With Global Business Opportunities Assessment With Revenue, Price And Gross Margin Analysis 2027 – Eurowire

The Neuroscience research report covers the current scenario and the growth prospects of the global Neuroscience industry forecast 2020 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence which play a vital part in strategizing. Neuroscience manufacturers and is a important source of guidance and direction for companies and individuals interested in the Neuroscience industry.

The research presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data. The market report proposes complete synopsis of the market, covering several characteristics such as product definition, market breakdown based on several constraints, supply chain analysis, and the fundamental Key Players outlook.

Download FREE PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2487

Market-research techniques encompass qualitative techniques. The report helps the user to strengthen decisive power to plan their strategic moves to launch or expand their businesses by offering them a clear picture of this market. Neuroscience Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Neuroscience market.

The Neuroscience Market report provides valuable and unique information which is very essential. Further it also covers key players, application and future market condition. This information is extremely important for new and growing company to mark themself over the market

This report is segmented into several key Regions, consumption, revenue and market growth with high frequency pivot in these regions, from2020 to 2027 (forecast), covering United States, Europe, China, Japan, India, and Southeast Asia and focused on different aspects like market revenue, consumption, production, market share besides the growth pace.

Competitive Analysis:

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players includes its basic information like legal name, website url, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.

Major Players Are: Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Blackrock Microsystems LLC, Femtonics Ltd., Intan Technologies, LaVision Biotec GmbH, Mediso Medical Imaging Systems, Neuralynx Inc., NeuroNexus Technologies, Inc., Newport Corporation, Plexon Inc., Noldus Information Technology, Scientifica Ltd., Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

Important Features of the Neuroscience Market:

Buy This Research Study Report For Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/2487

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

See the article here:
Neuroscience Market Analysis With Global Business Opportunities Assessment With Revenue, Price And Gross Margin Analysis 2027 - Eurowire